Time filter

Source Type

News Article | December 19, 2016
Site: www.24-7pressrelease.com

BOSTON, MA, December 19, 2016-- Lawrence Thacher Perera has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.With more than five and a half decades of professional experience, Mr. Perera brings that experience to his current role with Hemenway & Barnes, where he has served as of counsel since 2007. Prior to his admission to the bar, Mr. Perera earned a Bachelor of Arts and a Bachelor of Laws from Harvard University. Following graduation, he served as a law clerk to Hon. R. Ammi Cutter of the Massachusetts Supreme Judicial Court and then as an associate and a partner of Palmer & Dodge. In 1974, Mr. Perera was appointed a Judge of the Middlesex Probate Court where he served until 1979 when he became a partner in the firm of Hemenway & Barnes and where he is currently of counsel.Mr. Perera is a member of the Boston and Massachusetts Bar Associations, the American College of Trust and Estate Counsel, the American Academy of Matrimonial Lawyers, and the American Law Institute. He has been featured in Who's Who in Finance and Industry, Who's Who in American Law, Who's Who in America, and Who's Who in the World.Mr. Perera's civic and charitable activities have included the Boston Opera Association, the Boston Finance Commission, the Back Bay Architectural Commission, Wang Center for the Performing Arts, the Boston Athenæum, and the Humane Society of the Commonwealth of Massachusetts.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis now publishes many Who's Who titles, including Who's Who in America , Who's Who in the World , Who's Who in American Law , Who's Who in Medicine and Healthcare , Who's Who in Science and Engineering , and Who's Who in Asia . Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com


Massachusetts Cannabis Market Annual Retail Sales Estimated to reach US$1.1 Billion by 2020; First Harvest Expected During Third Quarter of 2017 TORONTO, ON and NEW YORK, NY--(Marketwired - March 02, 2017) - iAnthus Capital Holdings, Inc. ("iAnthus" or "the Company"), ( : IAN), a provider of capital investment and management services to licensed cannabis cultivators, processors and dispensaries throughout the United States, is pleased to announce that construction has commenced on a state-of-the-art cannabis cultivation and processing facility in Holliston, Massachusetts for the benefit of Mayflower Medicinals, Inc. ("Mayflower"), a Massachusetts non-profit Registered Marijuana Dispensary ("RMD") license holder affiliated with the Company. The 36,000 square foot facility is expected to have an annual production capacity of 8,700 pounds and will cost approximately US$6.0 million, which amount is fully funded. Based on current average sales prices, the production volume can support in excess of US$35 million in annual revenues. The space is located within an existing warehouse building and the initial interior demolition to prepare for tenant improvements and installation of cultivation and processing equipment has been completed. Cultivation is expected to begin during the second quarter of 2017 with first harvest expected in the third quarter of 2017. The facility is within a modular industrial complex, which will present future opportunities for expanding capacity beyond the initial 36,000 square feet. To date, iAnthus has invested US$3.0 million in support of Mayflower's operations and an incremental US$7.5 million is expected to be invested to complete the entire build out of the cultivation and processing facility and three dispensaries. The incremental amount of required capital will be funded from iAnthus' current cash position. It is anticipated that a newly-formed entity that is 79% owned by iAnthus will enter into a definitive agreement with Mayflower to provide financing, real estate and equipment leasing, intellectual property licensing, and certain management services in support of Mayflower's mission to provide medical marijuana to qualified patients in Massachusetts. "Our investment in support of Mayflower's mission and operations positions iAnthus to realize significant cash flows once the cultivation facility and dispensaries are fully built out and Mayflower commences sales," said Randy Maslow, President of iAnthus. Mr. Maslow further stated: "We believe Mayflower Medicinals is well positioned in the medical marijuana market, given its strategic locations and the fact that, as of February 28, 2017, only nine Registered Marijuana Dispensaries (RMDs) have been approved by the Commonwealth to dispense medical marijuana. Currently, Mayflower Medicinals holds one of only three RMD registrations issued for dispensaries in Boston, the largest city in Massachusetts. We expect Mayflower to have a first mover advantage and be able to capitalize on the robust growth from the anticipated demand as the market grows into its forecasted US$1.1 billion size." As announced in September 2016, Mayflower has been provisionally awarded two licenses by the Commonwealth of Massachusetts to operate medical dispensaries, including one in the highly desirable Allston-Brighton neighborhood of Boston. The licenses are vertically integrated and allow for the development and operation of the associated Holliston cultivation and processing facility. The dispensaries are expected to open for business during the fourth quarter of 2017 under the operational direction of Jaime Lewis, a prominent medical marijuana senior manager with over a decade of cannabis cultivation, production, and dispensary operations experience across the United States. Mayflower has a pending application with the Commonwealth of Massachusetts for a third dispensary license. Once fully operational, the Holliston cultivation and processing facility will supply the two dispensaries currently licensed to Mayflower and any future dispensaries licensed to Mayflower, as well as wholesale supply to other dispensaries in Massachusetts. "We are excited to have broken ground on our cultivation facility and look forward to the start-up of cultivation in the second quarter of 2017 and the subsequent opening of our first two dispensaries, including one in Boston, the largest city in the state," said John Henderson, CEO of Mayflower. The number of patients that have purchased medical marijuana in Massachusetts has tripled over the past twelve months, to approximately 18,000 per month. Total active patient certifications roughly doubled in 2016 from approximately 22,000 in December 2015 to approximately 40,000 currently, with 179 physicians registered to certify new patients. Massachusetts joins Maine as one of only two states on the East Coast where voters have approved adult recreational cannabis sales. According to Arcview Market Research, an industry leader in cannabis research, the Massachusetts legal cannabis market is expected to generate over US$1.1 billion in annual sales by 2020. In addition, the Massachusetts population has experienced rapid growth in recent years, with the state's population now totaling over 6.7 million people, largely concentrated in urban and exurban municipalities. "Our investment in Massachusetts highlights our goal of deploying shareholder capital in the most efficient way possible, generating high rates of return while also minimizing downside risk. We look forward to making additional investments that generate similar cash flow and equity-like returns in other U.S. states," said Julius Kalcevich, CFO of iAnthus. iAnthus plans to provide further updates to shareholders during the Mayflower construction process. iAnthus Capital Holdings, Inc., through its 100% owned subsidiary, iAnthus Capital Management, LLC, delivers a comprehensive solution for financing and managing licensed cannabis cultivators, processors and dispensaries throughout the United States. Founded by entrepreneurs with decades of experience in investment banking, corporate finance, law and healthcare services, iAnthus provides a unique combination of capital and hands-on operating and management expertise. The Company harnesses these skills to support a diversified portfolio of cannabis industry investments for our shareholders. For more information, visit www.ianthuscapital.com. Mayflower Medicinals is a "patient-first" non-profit healthcare organization, dedicated to providing the highest-quality medical cannabis products and services in a safe, secure and professionally managed environment in the Commonwealth of Massachusetts. Mayflower has received two provisional licenses to operate Registered Marijuana Dispensaries in Massachusetts, and has received approvals to operate its cultivation center in Holliston, MA. Mayflower is affiliated with iAnthus Capital Management, LLC and Randy Maslow and John Henderson of iAnthus are members of the Mayflower Board of Directors. Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in iAnthus' periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements. Forward-looking statements may include, without limitation, statements including statements related to iAnthus' future growth and the operations of its partners. Although iAnthus has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US Federal laws; change in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. iAnthus disclaims any intention or obligation to update or revise such information, except as required by applicable law, and iAnthus does not assume any liability for disclosure relating to any other company mentioned herein. The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.


COPENHAGEN, 16-Feb-2017 — /EuropaWire/ — The untapped offshore wind energy potential in the US is estimated by the Office of Energy Efficiency and Renewable Energy to be more than 2,000 gigawatts (GW), nearly double the nation’s annual electricity use. Yet the first offshore wind farm in the US was completed just last year off the coast of Rhode Island. The Massachusetts Clean Energy Center (MassCEC) last week awarded Ramboll and team partners a contract to study this untapped potential within the Commonwealth of Massachusetts. The Offshore Wind Ports & Infrastructure Assessment encompasses a series of tasks, key among them an evaluation of underdeveloped waterfront sites in Massachusetts that could potentially be acquired and developed through private investment to support both near-term and long-term offshore wind activities. The study will yield a series of property assessments to guide offshore wind developers, manufacturers and private investors in their selection of sites to fabricate, manufacture, stage, deploy and service offshore wind components in Massachusetts and along the East Coast. Project Principal David Lis says, “This is an exciting opportunity, since it literally positions us on the ground floor of a potentially huge transformation within the US energy industry. Ramboll has been a key force in the offshore wind industry in the Nordics and across Europe, so the experience and expertise that we bring to this project and to the industry generally are invaluable.” The MassCEC study team includes Ramboll, Apex and other local engineering firms; the University of Massachusetts (Boston) Urban Harbors Institute; and Tufts University. The project brings together leading global experts in offshore wind development; experienced Massachusetts-based engineers, and environmental and port professionals with direct knowledge of the project sites in the study area and in the US offshore wind marketplace; world-renowned researchers in port development and offshore wind energy production; and key members of the supply chain that will build the new offshore wind industry in the US.


News Article | February 28, 2017
Site: www.prweb.com

MTPV Power Corporation (http://www.mtpv.com), a clean energy company that coverts heat to electricity using semiconductor chips, has announced that it is a Massachusetts Clean Energy Center (MassCEC) InnovateMass program awardee, receiving a grant to deploy its EBLADE™ Power Platform waste heat to power solution in a production glass manufacturing environment. The InnovateMass program provides strategic funding and support to companies on the threshold of new cleantech product commercialization. InnovateMass funding covers a wide array of clean energy technologies, with an emphasis on specific energy challenges that are priority areas for the Commonwealth of Massachusetts. Ardagh Group, a global leader in the packaging industry with more than 23,000 employees in 109 facilities and 22 countries worldwide, is working with MTPV to implement and manage this clean energy site demonstration project. The project will take place at the Ardagh Group, Glass – North America facility in Milford, MA, which manufactures approximately 2.4 million glass bottles per day. “MTPV Power Corporation is honored to receive MassCEC’s InnovateMass grant. The InnovateMass program is an outstanding resource for clean energy companies in the Commonwealth of Massachusetts,” said MTPV’s President & CEO David Mather. “The funding and support provided by the InnovateMass program and the outstanding collaboration of Ardagh Group accelerates the commercialization of our groundbreaking waste heat to electricity conversion technology.” “By making key investments in early-stage companies, we can help these local companies address persistent funding gaps and increase business opportunities,” said MassCEC CEO Stephen Pike. “Through continued assistance to help develop Massachusetts’ vibrant innovation sector, the Commonwealth is positioned to benefit from increased job creation, technology development, and economic activity throughout the state.” "Ardagh Group continually invests in systems and processes that improve the efficiency of our operations, reduce costs and increase competitiveness,” said Ted Moser, Manager, Energy for Ardagh Group, Glass – North America. "Our goal is to become the leading supplier of inherently sustainable glass packaging, and the ability to convert our waste heat directly into electricity improves competitiveness while having a direct environmental impact, supporting both our business and sustainability objectives.” About MTPV Power Corporation (http://www.mtpv.com) MTPV is a clean energy semiconductor company using its breakthrough technology to harness the world’s heat and convert it to electricity. For more information, visit http://www.mtpv.com and connect with MTPV on LinkedIn, Facebook and Twitter. About Ardagh Group (http://www.ardaghgroup.com) Ardagh Group is a global leader in glass and metal packaging solutions, producing packaging for most of the world's leading food, beverage and consumer care brands. We operate 109 facilities in 22 countries, employ over 23,000 people and have global sales exceeding $8.8 billion (Eur €7.9 billion). About MassCEC (http://www.masscec.com/) The Massachusetts Clean Energy Center (MassCEC) is dedicated to accelerating the success of clean energy technologies, companies, and projects in the Commonwealth—while creating high-quality jobs and long-term economic growth for the people of Massachusetts. Since its inception in 2009, MassCEC has helped clean energy companies grow, supported municipal clean energy projects, and invested in residential and commercial renewable energy installations creating a robust marketplace for innovative clean technology companies and service providers. Massachusetts Energy and Environmental Affairs Secretary Matthew Beaton chairs MassCEC’s board of directors.


News Article | February 24, 2017
Site: www.prweb.com

The 5th Annual Humans to Mars Summit (H2M) will be held from May 9-11, 2017 at The George Washington University in Washington, DC. H2M is the largest conference in the world focused on the goal of sending humans to Mars and will feature some of the most prominent and influential people in business, government and academia. The conference will explore critical policy goals and technology solutions required for the human exploration of Mars and the significant progress that has been made since the first H2M was held in 2013. “Children born in 2017 are more likely than any generation before them to witness, before their 18th birthday, humans walk on another planet for the first time,” said Explore Mars, CEO Chris Carberry. “For more than five years, the Humans to Mars Summit has been at the forefront of policy and technology decisions that have had a major impact on U.S. space policy. Today we have unprecedented support for Mars exploration from Congress, industry, and the general public. If we make the right decisions, humans will be on the surface of Mars within the next two decades, and the economic and scientific benefits to our country and the world will be unprecedented.” H2M 2017 will be a platform for discussion on major technical, scientific, and policy challenges that need to be overcome in order to send humans to Mars by the early 2030s. The Summit will also feature topics such as international partnerships and cooperation, the impact on small business and innovation, Hollywood and the Mars story, risk tolerance in space exploration, the role of the Moon in sending humans to Mars, and space diplomacy. Confirmed speakers include: Buzz Aldrin (Apollo XI, Gemini XII), William Gerstenmaier (NASA: Associate Administrator, HEO), Penny Boston (NASA: Director, Astrobiology Institute), Steve Jurczyk (NASA: Associate Administrator, STMD), Clementine Poidatz (National Geographic Series, Mars), John Grunsfeld (former NASA Associate Administrator and astronaut), Artemis Westenberg (President, Explore Mars, Inc), Thomas Zurbuchen (NASA: Associate Administrator, SMD), Abigail 'Astronaut Abby' Harrison (Student; The Mars Generation), Jim Cantrell (CEO of Vector Space Systems), James Green (NASA: Director, Planetary Science), Janet Ivey (Janet's Planet), Joe Cassady (Aerojet Rocketdyne: Executive Director, Space), Mat Kaplan (Planetary Radio, The Planetary Society) and Ann Merchant (Science and Entertainment Exchange). Said Explore Mars President, Artemis Westenberg, “H2M will host substantive NASA workshops on policy, STEaM competitions for our youth and important debates on strategies for space transportation and human habitats. This is the single best opportunity for all of us to come together and advance the mission that will one day make humans a two-planet species.” For registration information visit http://h2m.exploremars.org. To become an event sponsor, please contact carberry(at)exploremars(dot)org. About Explore Mars Explore Mars was created to advance the goal of sending humans to Mars within the next two decades. To further that goal, Explore Mars conducts programs and technical challenges to stimulate the development and improvement of technologies that will make human Mars missions more efficient and feasible. To advance the idea of Mars as a habitable planet, Explore Mars challenges educators to use Mars in the classroom as a tool to teach standard STEM curricula. Explore Mars, Inc. is a 501(c)(3) non-profit corporation organized in the Commonwealth of Massachusetts. Donations to Explore Mars are tax-deductible. Contact Explore Mars via its website or email info(at)ExploreMars(dot)org.


News Article | February 20, 2017
Site: www.marketwired.com

WEST SPRINGFIELD, MA--(Marketwired - February 20, 2017) - Two West Springfield-based officials with CleanSlate Centers, a leader in providing care to those suffering from opioid and alcohol addiction, have been asked to join the District Attorney's Hampden County Addiction Task Force (HCAT). CleanSlate's Katie Roberts, Care Coordinator, and Jonathan Candee, manager for the West Springfield center located at 900 Memorial Ave., have accepted the opportunity to work more closely with the DA office, local healthcare providers, and other service providers in the region to help prevent and treat opioid addiction. "Together with HCAT, we are not only making great strides in the fight against substance abuse but also helping to erase the stigma of addiction," said Candee. "Successful community partnerships are vital to treating addiction, and I'm confident the residents of West Springfield will see great benefit from CleanSlate and HCAT joining forces. We're excited about the opportunity to help impact more families in our area." Founded in 2009 in response to the growing opioid epidemic facing the country, CleanSlate has treated more than 14,000 patients in some of the states hit hardest by the opioid epidemic, including Massachusetts, Indiana and Pennsylvania. Headquartered in Northampton, CleanSlate operates 14 treatment centers across Massachusetts, including a location in Lynn which opens this week. CleanSlate's treatment methods are in accordance with the American Society of Addiction Medicine (ASAM) -- the nation's leading addiction medicine society representing 4,000 physicians, clinicians and other professionals -- which dictates opioid addiction be defined as a primary, chronic and relapsing brain disease. "At CleanSlate, we know that opioid addiction is best treated as the chronic disease it is," said Kelly J. Clark, M.D., Chief Medical Officer of CleanSlate and President-elect of ASAM. "We currently treat thousands of patients for opioid and alcohol addiction in a comfortable outpatient environment with a full-time, dedicated team of physicians and advanced-practice clinicians. Our ultimate goal is to help these patients achieve the life they want and deserve -- a 'clean slate' from which to thrive." Drug overdose deaths from opioids remain on the rise in Massachusetts according to the Health and Human Services Division of the Commonwealth of Massachusetts. In 2015, the rate of unintended overdoses from opioids was 24.6 deaths per 100,000 residents, which represents a 23 percent increase from the 2014 rate.i CleanSlate Centers was founded in 2009 in response to the growing opioid epidemic facing the country. A multi-state network of physician-led outpatient addiction treatment centers, CleanSlate provides medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices. CleanSlate's proven model of individualized care gives patients the tools and support they need to achieve long-term success. In recognition of their innovation and effectiveness, CleanSlate's treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA). In 2014 CleanSlate partnered with Apple Tree Partners, a growth equity fund, to help expand efforts geographically and increase access to care in underserved communities with demonstrated need.


News Article | March 3, 2017
Site: www.24-7pressrelease.com

FLORENCE, ITALY, March 03, 2017-- Peter Forbes has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.Peter Forbes is an architect, designer and design educator living in Florence, Italy, with a professional practice based there and in Seal Harbor, Maine, USA. He holds dual citizenship from the United States and Italy.Forbes worked on ranches throughout the western United States before graduating with a Bachelors degree in architecture from the University of Michigan. He then apprenticed in several architectural firms in Chicago, Illinois, USA, most notably a brief internship with the office of Mies van der Rohe and subsequently with the Chicago office of Skidmore, Owings and Merrill. Following this early experience he earned a Master's degree in architecture and urbanism from Yale University.Upon graduating from Yale, Forbes moved to Boston where he completed his apprenticeship as an architect with the firm of Planning/Architecture/Research/Design Team (PARD) before starting his own practice first with partners as Forbes Hailey Jeas Erneman Architects and then on his own as Peter Forbes and Associates.Prior to starting Peter Forbes and Associates, Forbes served as the architect member of the Commonwealth of Massachusetts Special Commission Concerning State and County Buildings, known as the Ward Commission after its chairman John William Ward, then president of Amherst College. The Commission was charged with investigating allegations of corruption and maladministration in public building procurement. The Commission sat from 1978 to 1981 finding a vast scope of bribery and shoddy building in the Commonwealth. Based upon their findings the Commission drafted legislation establishing the first state-level office of inspector general in the United States and sweeping reforms to the procurement process. Forbes, as an architect, was the principal drafter of the procurement legislation. The bills were passed into law by the Massachusetts legislature.As a result of his experience on the Ward Commission, Forbes became the head of the ethics committee of the Boston Society of Architects and then a member of the Ethics Task Force of the National American Institute of Architects which drafted a uniform code of ethics adopted by the AIA. He subsequently was appointed to the National Judicial Council of the AIA charged with adjudicating the code of ethics.Largely as a result of his public service and service to the architectural profession, Forbes was elected to the American Institute of Architects College of Fellows, the Institute's highest membership honor. At the time of his investiture, Forbes was the youngest member so honored in the history of the Institute.Forbes's involvement with the leadership of the profession continued with service to the Boston Society of Architects as Commissioner for Public Affairs, Vice President and President of the society. He was also elected president of the Massachusetts State Association of Architects.Peter Forbes and Associates quickly became known as a highly skilled "boutique" design firm specializing in meticulously designed and detailed projects for demanding private clients. The work ranged in type and scale from single-family residential buildings to institutions such as the International Tennis Hall of Fame and specialized commercial clients like Origins Cosmetics company, a division of Estee Lauder Companies.The firm's projects became widely published in the architectural press throughout the world and received multiple design awards (see list of publications and awards). Featured in many books on design, the work was the subject of a monograph on the firm's residential work in 1997, Ten Houses; Peter Forbes and Associates. In 2000 the firm name was changed to Peter Forbes, FAIA, Architects.In addition to his work in architecture Forbes has always designed furniture, furnishings and objects. All of the furniture for the Origins Cosmetics stores was designed by Forbes as were many pieces of furniture for residential clients. This work continued in the Florence office with designs for objects from companies such as Alessi and San Lorenzo Silver, custom carpets for Boralevi Carpets, and furniture for Sedia Company, Franco Mobili, custom one-off pieces and experimental prototypes for companies such as Poltrona Frau.Parallel to his professional career Peter Forbes has taught architecture and design continuously since the earliest days of his office. Beginning in 1972 as an instructor at the Boston Architectural Center Forbes has been a visiting critic or professor in residence at many schools of architecture and design. He has been a visiting critic and subsequently Thomas S. Monahan Distinguished Visiting Professor and Guido A. Binda Visiting Lecturer at the University of Michigan. He served as a visiting critic and was awarded the G. Truman Ward Visiting Lectureship at Virginia Polytechnic and State University (Virginia Tech).Forbes has been a visiting professor at Technical University of Nova Scotia and for several years at the Harvard University Graduate School of Design. He has been a visiting critic at numerous schools of design including Columbia University, Catholic University of America - Washington DC and Rome, Italy -Lawrence Technical University, Syracuse University Florence, Italy program, Kent State University Florence, Italy program and Wentworth Institute of Technology. In 1991 Wentworth Insitute of Technology honored Forbes with the honorary degree Doctor of Engineering Technology, the Institute's highest accolade. Since 2009 Forbes has been senior instructor in design at the Florence Institute of Design International, Florence, Italy.Peter Forbes has three children: Alexander John Forbes and Anne deMarcken Forbes from his first marriage both of whom live and work in Olympia, Washington, USA, and Allegra Longfellow Forbes from his second marriage, resident of Florence, Italy, presently studying at Barnard College of Columbia University, New York City, USA.Forbes is a proprietor of the Boston Athenaeum, a life member of the Society of Architectural Historians and the Nature Conservancy. An avid sailor, he is a member of the Seal Harbor Yacht Club, Seal Harbor, Maine, USA and the Compagnia della Vela, Venice, Italy.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com


News Article | February 24, 2017
Site: www.accesswire.com

DENVER, CO / ACCESSWIRE / February 24, 2017 / AmeriCann, Inc. (OTCQX: ACAN), an Ag-Tech company that is developing sustainable, state-of-the-art medical cannabis cultivation properties discussed Thursday's White House regular news briefing. AmeriCann has reviewed the Press Secretary's comments, in response to a reporter's question, related to the enforcement of federal regulations and the cannabis industry. Management is encouraged that the White House has acknowledged its support for state regulated medical marijuana programs. Press Secretary Sean Spicer affirmed the President's support for medical cannabis and noted that states are entitled to regulate medical marijuana in accordance with state law. Since inception, AmeriCann has been focused on serving the regulated medical marijuana industry. AmeriCann, an Ag-Tech company, is developing a 53-acre property in Massachusetts as the Massachusetts Medical Cannabis Center (the "MMCC"). The MMCC is approved for 1 million square feet and is expected to be one of the most technologically advanced cultivation facilities in the nation. The Massachusetts Medical Cannabis Center in Freetown, Massachusetts was designed and is being developed to support the medical cannabis industry. AmeriCann does not expect any impact to the development schedule of MMCC and to have the infrastructure open by the end of 2017. Given that our current plans are exclusively for serving the medical market, a change in federal policy regarding the non-medical market, as Press Secretary Spicer suggested, would have no impact on our project or company. With the passage of the Adult Use ballot initiative in November, the Commonwealth of Massachusetts is not expecting regulations, licensing and commencement of Adult-Use cannabis sales to commence until the middle of 2018. There is not an existing regulated Adult-Use market in Massachusetts. Massachusetts Governor Charlie Baker stated in the Boston Globe on Thursday that, "The voters of Massachusetts have spoken on this issue," when they approved recreational use in November, and emphasized the Baker administration will continue to work to "move forward" with the new law. Medical cannabis sales made up $437 million dollars in total sales during 2016 in Colorado. It is a significant segment of the overall cannabis industry. Massachusetts's medical cannabis market is just starting to develop and is expected to be comparable in size to Colorado when mature. A Quinnipiac University Poll released on February 23rd, 2017 shows that 93% of Americans support medical marijuana. With the results of the November 2016 election results, over 60% of the US Population now live in states where medical cannabis is now legal. Of the 28 states that have implemented legal cannabis programs, only 8 have approved Adult-Use. AmeriCann is a publicly traded Ag-Tech company that plans to develop sustainable, state-of-the-art medical cannabis cultivation properties throughout the country. The Company has over 1,000,000 square feet of facilities in the planning and design stages of development. The Company has designed a proprietary line of cannabis infused products which will be branded and licensed to companies in regulated markets. AmeriCann, Inc. is a Certified B Corp, an acknowledgment of the company's commitment to social and environmental ethics, transparency and accountability. AmeriCann became the first public cannabis company to earn this respected accreditation. More information about the Company is available at: www.americann.co or follow AmeriCann on Twitter @ACANinfo The Massachusetts Medical Cannabis Center is approved for nearly 1,000,000 square feet of medical cannabis cultivation and processing in Freetown, Massachusetts. The state-of-the-art, sustainable, greenhouse project will consist of multiple planned phases for licensed businesses in the Massachusetts medical marijuana market. AmeriCann's Cannopy System uniquely combines expertise from traditional horticulture, lean manufacturing, regulatory compliance and cannabis cultivation to create superior facilities and procedures. The first phase of the project consists of 130,000 sq. ft. of cultivation and processing infrastructure. AmeriCann can expand the first phase to approximately 600,000 sq. ft., based on patient demand. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended September 30, 2016, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov.


News Article | February 24, 2017
Site: marketersmedia.com

DENVER, CO / ACCESSWIRE / February 24, 2017 / AmeriCann, Inc. (OTCQX: ACAN), an Ag-Tech company that is developing sustainable, state-of-the-art medical cannabis cultivation properties discussed Thursday's White House regular news briefing. AmeriCann has reviewed the Press Secretary's comments, in response to a reporter's question, related to the enforcement of federal regulations and the cannabis industry. Management is encouraged that the White House has acknowledged its support for state regulated medical marijuana programs. Press Secretary Sean Spicer affirmed the President's support for medical cannabis and noted that states are entitled to regulate medical marijuana in accordance with state law. Since inception, AmeriCann has been focused on serving the regulated medical marijuana industry. AmeriCann, an Ag-Tech company, is developing a 53-acre property in Massachusetts as the Massachusetts Medical Cannabis Center (the "MMCC"). The MMCC is approved for 1 million square feet and is expected to be one of the most technologically advanced cultivation facilities in the nation. The Massachusetts Medical Cannabis Center in Freetown, Massachusetts was designed and is being developed to support the medical cannabis industry. AmeriCann does not expect any impact to the development schedule of MMCC and to have the infrastructure open by the end of 2017. Given that our current plans are exclusively for serving the medical market, a change in federal policy regarding the non-medical market, as Press Secretary Spicer suggested, would have no impact on our project or company. With the passage of the Adult Use ballot initiative in November, the Commonwealth of Massachusetts is not expecting regulations, licensing and commencement of Adult-Use cannabis sales to commence until the middle of 2018. There is not an existing regulated Adult-Use market in Massachusetts. Massachusetts Governor Charlie Baker stated in the Boston Globe on Thursday that, "The voters of Massachusetts have spoken on this issue," when they approved recreational use in November, and emphasized the Baker administration will continue to work to "move forward" with the new law. Medical cannabis sales made up $437 million dollars in total sales during 2016 in Colorado. It is a significant segment of the overall cannabis industry. Massachusetts's medical cannabis market is just starting to develop and is expected to be comparable in size to Colorado when mature. A Quinnipiac University Poll released on February 23rd, 2017 shows that 93% of Americans support medical marijuana. With the results of the November 2016 election results, over 60% of the US Population now live in states where medical cannabis is now legal. Of the 28 states that have implemented legal cannabis programs, only 8 have approved Adult-Use. AmeriCann is a publicly traded Ag-Tech company that plans to develop sustainable, state-of-the-art medical cannabis cultivation properties throughout the country. The Company has over 1,000,000 square feet of facilities in the planning and design stages of development. The Company has designed a proprietary line of cannabis infused products which will be branded and licensed to companies in regulated markets. AmeriCann, Inc. is a Certified B Corp, an acknowledgment of the company's commitment to social and environmental ethics, transparency and accountability. AmeriCann became the first public cannabis company to earn this respected accreditation. More information about the Company is available at: www.americann.co or follow AmeriCann on Twitter @ACANinfo The Massachusetts Medical Cannabis Center is approved for nearly 1,000,000 square feet of medical cannabis cultivation and processing in Freetown, Massachusetts. The state-of-the-art, sustainable, greenhouse project will consist of multiple planned phases for licensed businesses in the Massachusetts medical marijuana market. AmeriCann's Cannopy System uniquely combines expertise from traditional horticulture, lean manufacturing, regulatory compliance and cannabis cultivation to create superior facilities and procedures. The first phase of the project consists of 130,000 sq. ft. of cultivation and processing infrastructure. AmeriCann can expand the first phase to approximately 600,000 sq. ft., based on patient demand. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended September 30, 2016, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov. DENVER, CO / ACCESSWIRE / February 24, 2017 / AmeriCann, Inc. (OTCQX: ACAN), an Ag-Tech company that is developing sustainable, state-of-the-art medical cannabis cultivation properties discussed Thursday's White House regular news briefing. AmeriCann has reviewed the Press Secretary's comments, in response to a reporter's question, related to the enforcement of federal regulations and the cannabis industry. Management is encouraged that the White House has acknowledged its support for state regulated medical marijuana programs. Press Secretary Sean Spicer affirmed the President's support for medical cannabis and noted that states are entitled to regulate medical marijuana in accordance with state law. Since inception, AmeriCann has been focused on serving the regulated medical marijuana industry. AmeriCann, an Ag-Tech company, is developing a 53-acre property in Massachusetts as the Massachusetts Medical Cannabis Center (the "MMCC"). The MMCC is approved for 1 million square feet and is expected to be one of the most technologically advanced cultivation facilities in the nation. The Massachusetts Medical Cannabis Center in Freetown, Massachusetts was designed and is being developed to support the medical cannabis industry. AmeriCann does not expect any impact to the development schedule of MMCC and to have the infrastructure open by the end of 2017. Given that our current plans are exclusively for serving the medical market, a change in federal policy regarding the non-medical market, as Press Secretary Spicer suggested, would have no impact on our project or company. With the passage of the Adult Use ballot initiative in November, the Commonwealth of Massachusetts is not expecting regulations, licensing and commencement of Adult-Use cannabis sales to commence until the middle of 2018. There is not an existing regulated Adult-Use market in Massachusetts. Massachusetts Governor Charlie Baker stated in the Boston Globe on Thursday that, "The voters of Massachusetts have spoken on this issue," when they approved recreational use in November, and emphasized the Baker administration will continue to work to "move forward" with the new law. Medical cannabis sales made up $437 million dollars in total sales during 2016 in Colorado. It is a significant segment of the overall cannabis industry. Massachusetts's medical cannabis market is just starting to develop and is expected to be comparable in size to Colorado when mature. A Quinnipiac University Poll released on February 23rd, 2017 shows that 93% of Americans support medical marijuana. With the results of the November 2016 election results, over 60% of the US Population now live in states where medical cannabis is now legal. Of the 28 states that have implemented legal cannabis programs, only 8 have approved Adult-Use. AmeriCann is a publicly traded Ag-Tech company that plans to develop sustainable, state-of-the-art medical cannabis cultivation properties throughout the country. The Company has over 1,000,000 square feet of facilities in the planning and design stages of development. The Company has designed a proprietary line of cannabis infused products which will be branded and licensed to companies in regulated markets. AmeriCann, Inc. is a Certified B Corp, an acknowledgment of the company's commitment to social and environmental ethics, transparency and accountability. AmeriCann became the first public cannabis company to earn this respected accreditation. More information about the Company is available at: www.americann.co or follow AmeriCann on Twitter @ACANinfo The Massachusetts Medical Cannabis Center is approved for nearly 1,000,000 square feet of medical cannabis cultivation and processing in Freetown, Massachusetts. The state-of-the-art, sustainable, greenhouse project will consist of multiple planned phases for licensed businesses in the Massachusetts medical marijuana market. AmeriCann's Cannopy System uniquely combines expertise from traditional horticulture, lean manufacturing, regulatory compliance and cannabis cultivation to create superior facilities and procedures. The first phase of the project consists of 130,000 sq. ft. of cultivation and processing infrastructure. AmeriCann can expand the first phase to approximately 600,000 sq. ft., based on patient demand. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended September 30, 2016, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov.


Patent
Commonwealth of Massachusetts | Date: 2010-09-10

Methods of modulating the immune response using pharmaceutical compositions containing crystalline adjuvants are described. In various embodiments the crystalline adjuvants are selected from the group consisting of monosodium urate (MSU), xanthine, basic calcium phosphate (BCP), calcium pyrophosphate dihydrate (CPPD), hydroxyapatite, calcium oxalate, cholesterol, lipid liquid, other crystalline lipids, lithium heparin, talc, and starch.

Loading Commonwealth of Massachusetts collaborators
Loading Commonwealth of Massachusetts collaborators